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Is it worthwhile to conduct a randomized
controlled trial of glaucoma screening in
the United Kingdom?
Jennifer Burr1, Rodolfo Herna´ndez2, Craig Ramsay3,
Maria Prior4, Susan Campbell5, Augusto Azuara-Blanco6,
Marion Campbell7, Jill Francis8 and Luke Vale9
Abstract
Objectives: To assess the value of conducting a glaucoma screening randomized controlled trial in the UK.
Methods: Decision model based economic evaluation and value of information analysis. Model derived from a previous
health technology assessment. Model updated in terms of structure and parameter estimates with data from surveys,
interviews with members of the public and health care providers and routine sources.
Results: On average, across a range of ages of initiating screening (40–60 years), glaucoma prevalence (1–5%), screening
uptake (30–100%), and the performance of current case finding, screening was not cost-effective at a £30,000 threshold
per quality adjusted life year (QALY) from the perspective of the National Health Service (NHS). The societal value of
removing all uncertainty around glaucoma screening is £107 million at a threshold of £20,000 per QALY. For informing
policy decisions on glaucoma screening, reducing uncertainty surrounding the NHS and personal social care cost of sight
impairment (£74 million) was of most value, followed by reducing uncertainty in test performance (£14 million) and
uptake of either screening or current eye care (£8 million each).
Conclusions: A glaucoma screening trial in the UK is unlikely to be the best use of research resources. Further research
to quantify the costs of sight impairment falling on the NHS and personal social services is a priority. Further develop-
ment of glaucoma tests and research into strategies to promote the uptake of screening or current eye care such as
through the use of a behavioural intervention would be worthwhile.
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Introduction
Glaucoma, a chronic eye condition, is a leading cause
of avoidable blindness.1,2 Open angle glaucoma is the
commonest form.3 Sight loss from glaucoma can be
avoided as early treatment of the condition reduces
the risk of sight loss.4 However, in the UK around
3000 people are newly registered with sight impair-
ment due to glaucoma each year.5 Delayed detection
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and thus access to early treatment is the main risk
factor for sight loss6,7 and may be linked to areal or
individual socioeconomic deprivation.8–10 Delayed
access to treatment may occur at any stage of the
referral pathway. There may be patient delay in
terms of attendance for testing, process delay in
terms of missed detection, or system delay leading to
delayed referral for treatment.11–13 The public health
importance of glaucoma could indicate that a screen-
ing programme might be warranted. Before a screen-
ing policy is adopted evidence is required that the
beneﬁts of screening, namely reduced visual impair-
ment, outweigh any harms, for example anxiety
and cost.
An earlier evaluation using economic modelling
found that screening the UK population, selected on
age alone, was unlikely to be cost-eﬀective as the
prevalence is too low in all age groups (screening at
age 40 or 65 or 75).5,14 A surveillance programme
targeted to higher risk groups (a sibling with glau-
coma; ethnic minority groups; diabetics; or people
with ocular risk factors such as raised intraocular
pressure (IOP) and myopia) or those who do not nor-
mally use eye care might be worthwhile. The model-
ling evaluation, hereafter referred to as the Glaucoma
Screening Model, used the best data available but still
had some uncertainties: how best to screen (tests and
location); likely uptake of any screening programme;
and the eﬀectiveness and coverage of current eye care
services.
The most robust way to evaluate any proposed
screening programme is a randomized controlled trial
(RCT).15 There are no RCTs evaluating glaucoma
screening16 and any trial would need to be large and
thus costly. In a recent trial platform study,17 we under-
took a multicomponent mixed-methods approach to
provide evidence to inform the optimal design for a
trial. We followed the Medical Research Council guid-
ance for the development and evaluation of complex
interventions.18 Our initial work consisted of address-
ing the development of the screening test schedule and
the factors associated with motivation of the public
to attend for screening. We took a systematic, theory-
based approach to intervention development (identify-
ing the evidence, modelling process and developing
outcomes) and explored the feasibility (for service pro-
viders), acceptability (for providers and users), and
cost-eﬀectiveness (for health and social services) of
trial components. These individual components are
published elsewhere.19–21 In this paper, we report the
integration of the ﬁndings (revised screening test sched-
ule, likely uptake of screening and uptake of usual care)
into the glaucoma screening economic model to inform
whether a glaucoma screening trial would be
worthwhile.
Methods
We used a Markov model to assess how worthwhile a
glaucoma screening trial would be. We took the per-
spective that interventions compared within the model
could be delivered (technical feasibility) and were
acceptable (likely uptake by providers and the public)
in the context of the NHS.
We revised the structure of the existing Glaucoma
Screening Model5,14 with the most likely cost-eﬀective
glaucoma testing schedules that might be brought to
trial based on a prior Delphi survey19 and views of
NHS providers.20 We updated parameter estimates
for screening attendance based on our survey of the
public to identify factors associated with their hypo-
thetical intention (motivation) to attend an eye health
test. We also used data collected in the survey on
attendance by the public for an eye test within the
last three years to estimate uptake of the comparator
pathway within the model of opportunistic case ﬁnding
within current eye care.21 Costs were reported in 2010
prices. We sought estimates of attendance at eye care
services for several risk groups (age over 50, black eth-
nicity, diabetes, myopia, family history of glaucoma,
and low socioeconomic status from the British
Household Panel Survey data22 to develop and ﬁt the
probability distributions around the mean uptake of
current eye care for the general population and sub-
groups using the Excel add-on Oracle Crystal Ball.
Revised utility data were based on the EQ-5D-3L23
responses from 640 participants with ocular hyperten-
sion and glaucoma sampled from a secondary glau-
coma service (Prior, personal communication). All
other parameters were as detailed in the original
Glaucoma Screening Model.5,14 The model allowed
movement between health states every year, estimated
costs from NHS and personal social services perspec-
tives and used the EQ-5D-3L quality of life weights to
calculate quality adjusted life years (QALYs).
The base case analysis conducted from NHS per-
spective, considered a cohort of 40-year old males
with prevalence from 1% to 5%. Sex-speciﬁc variables
were not available for any of the model parameters
except for mortality. We used male mortality in the
base-case analysis, consistent with good modelling
practice, as they are a conservative assumption for
screening. Alternative likelihoods of attending screen-
ing (e.g. 30–100%) and estimated costs and QALYs
over their estimated lifetime with screening occurring
every 10 years were included. All costs and QALYs
were discounted at 3.5%. The results are presented as
incremental cost-eﬀectiveness ratios (ICERs).
We conducted sensitivity analyses to identify plaus-
ible situations where screening might be considered
worthwhile by varying screening start age and accuracy
of glaucoma detection within current eye care services.
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We used alternative data for uptake of current eye care
(based on the survey of the public21 and British
Household Panel Survey (BHPS) data) for the whole
population, for cohorts aged 50 and 60 as well as for
higher risk subgroups of the adult population: those
self-reported as having diabetes, sight problems in the
family (excluding using spectacles) as a proxy for family
history of glaucoma, and those at low household
income (below £10,000 a year). Data were not available
within the BHPS to investigate the impact of ethnicity
or myopia on the uptake rates of current eye care by
these groupings.
The eﬀect of including personal social services costs
was explored in the sensitivity analysis by incorporating
an annual cost of sight impairment from £1000 to
£40,000. The upper value is in line with personal
social services expenditure per person with sight impair-
ment for England for 2009–10.24 Variations in cost of
sight impairment were combined with variation in both
prevalence rates and screening uptake to identify situ-
ations where screening might be worthwhile. We
explored the impact of increasing screening uptake
because of a behavioural intervention and incorporat-
ing an additional cost for its provision. Without a
behavioural intervention, glaucoma screening uptake
was considered to be about 23% (based on our
survey where 45% of the sample had strong intention
scores (mean intention score of 7 on a 1–7 scale)21 and
the health behaviour literature that 50% of strong
intenders will perform the intended behaviour.25 We
varied screening uptake from 30% to 100% to explore
the impact of a behavioural intervention. Reﬂecting a
simple behavioural intervention such as an invitation
letter targeted to improve motivation by making it
easier to attend a screening appointment to a fully tai-
lored intervention, and thus more costly, to persuade
those with low intentions to attend. The mean QALYs
were expressed in pounds sterling by multiplying them
by the willingness to pay for a QALY threshold (e.g.
£30,000, see Figure 1).
We also explored whether enhanced current eye care
would be better than enrolling in a screening pro-
gramme by modifying the model in order to compare
two current practice strategies. Two uptake rates of
current eye care were compared using BHPS data:
6.5% (corresponding to the uptake rate of low
income groups) and 17% (estimated uptake of eye
care for people with diabetes).
All analyses incorporated probabilistic sensitivity
analyses where the statistical imprecision is allowed
for by sampling (e.g. 1000 times) from probability dis-
tributions attached to model mean parameter values.
The uncertainty in the model parameter values has
cost implications as the ‘correct’ strategy might not be
chosen. In eﬀect, if the analysis is run with alternative
parameter values the choice of strategy might diﬀer
from the strategy ﬁnally adopted. The sum of the bene-
ﬁts forgone for not being able to make the right deci-
sion due to this uncertainty is the expected value of
perfect information (EVPI), as perfect information
would eliminate the possibility of making wrong deci-
sions.26 The EVPI can be compared with the cost of
reducing uncertainty in the model by collecting further
information. The expected value of parameter perfect
information (EVPPI) is a similar concept but corres-
ponds to a particular parameter or group of parameters
in the model. EVPPI was calculated to identify model
parameters that contribute the most to the overall
model decision uncertainty.26 The total EVPI and
EVPPI were obtained by multiplying the EVPI and
EVPPI estimated at an individual level by the number
of individuals who would beneﬁt from the intervention
in a given period of time. We assumed 380,000 individ-
uals with undiagnosed glaucoma in the UK and an
annual incidence of 11,000 new cases5 a time horizon
of 10 years (representing the lifespan of the technology;
in this case a speciﬁc screening strategy) and a discount
rate of 3.5%.
Results
The revised model, now named the Glaucoma screening
Platform Study (GPS) model, considers four possible
screening strategies against a current practice compara-
tor (no screening). The pathways modelled are speciﬁed
in Box 1.
The screening test schedule, based on the views of
service providers in terms of practicality and equity,
was screening an inception cohort age 40. The screening
strategies allow for a technician as ﬁrst screening con-
tact. However, they diﬀer in the tests performed.
Glaucoma tests were either optic nerve photography
(ONP) or screening mode perimetry (a measure of
visual ﬁeld (VF) sensitivity) with or without tonometry
(a measure of IOP). For those testing positive two path-
ways were explored, a diagnostic reﬁnement step, using
a specialized optometrist to examine screen positives as
in the original model, or no referral reﬁnement with
screen test positives referred to a hospital based glau-
coma service.20 Tables 1 and 2 show the updated data
used in the GPS model. All other data in the model
remained as for original model.5,14
Base case analysis (inception cohort aged 40
estimated 1% glaucoma prevalence, screening
every 10 years and taking a NHS perspective)
On average, screening the general population selected
on age alone was not cost-eﬀective at a £30,000 thresh-
old (Table 3). It should be noted that as this is a
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Figure 1. Strategies with the highest net-benefit (defined as £30,000mean QALYs minus mean costs) for alternative values of
annual cost of sight impairment and percentage of screening uptake for a 50-year-old cohort. Willingness to pay is £30,000.
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population screening model we would expect a rela-
tively small proportion of individuals to be identiﬁed
with glaucoma and hence, on average for the popula-
tion, only small gains in beneﬁts.
Sensitivity analysis
Screening start age and performance of current eye care. For
cohorts starting at 50 and 60 years old, ICERs were,
regardless of the level of screening uptake, well above
the typically accepted threshold value of £30,000 (See
Supplementary material online, Tables 4 and 5). Similar
results were obtained when the sensitivity and speciﬁ-
city of case detection in current eye care were reduced
to plausible minimum levels (See Supplementary mate-
rial online, Tables 6 and 7).
Varying uptake of screening and current practice. Using alter-
native assumptions about the estimated uptake of current
eye care services, varying from low annual uptake 6.5%
(estimated uptake of eye care for low income households)
to 17% (estimated uptake of eye care for people with
diabetes) based upon BHPS data, and varying the
assumed uptake of screening from 50% to 100%, the
cost-eﬀectiveness of screening improved, although the
ICER remained well above a £30,000 threshold (See
Supplementary material online, Tables 8 and 9).
Cost of sight impairment. Figure 1 shows the two-way sen-
sitivity analyses results for the annual cost of sight
impairment versus the percentage of screening uptake.
That is, for each combination of cost of sight impair-
ment and proportion of screening uptake, the ﬁgure
which shows the strategy with the highest net-beneﬁt
(e.g. willingness to pay multiplied by the mean
QALYs minus mean cost), assuming a £30,000 willing-
ness to pay for a QALY.
For the illustrated cohort (inception cohort aged 50,
assumed 1% glaucoma prevalence and 17% annual
uptake of current practice21) none of the screening
pathways would have a higher net-beneﬁt compared
with current practice, unless the annual cost of sight
impairment is above £19,000. When the annual cost
of sight impairment is above £30,000 screening is
worthwhile if the uptake of screening is above 30%
(Figure 1(a)).
Figure 1. Continued.
(a) 1% glaucoma prevalence and 17%21 uptake current eye care practice. For the range of values selected for the annual cost of sight
impairment and uptake rate, only ‘current practice’, ‘GPS11d (IOPþVF)’ or ‘GPS11 (IOPþVF)’ are potentially cost-effective when
society is willing to pay £30,000 per QALY. The dashed line is illustrative. The screening strategy ‘GPS11d (IOPþVF)’ has the highest
net-benefit when the screening uptake is 30% and the annual cost of sight impairment is £30,000. The vertical continuous line at
£19,000 cost of sight impairment illustrates that screening is not cost-effective below this value, regardless of the screening uptake.
(b) 5% glaucoma prevalence and 17%22 uptake of current eye care.
The dashed line is illustrative. The screening strategy ‘GPS11d (IOPþVF)’ has the highest net-benefit for screening attendance of 40%
and annual cost of sight impairment just above £4500. The vertical continuous line at £3000 cost of sight impairment illustrates that
screening by any pathway is not cost-effective below this value, regardless of screening uptake.
(c) 1% glaucoma prevalence rate and 6.5%22 uptake of current eye care. The dashed line is illustrative. The screening strategy ‘GPS11d
(IOPþVF)’ having the highest net-benefit for screening attendance of 40% and annual cost of sight impairment above £18,000. IOP:
intraocular pressure; GPS: Glaucoma screening Platform Study; QALY: quality adjusted life years; VF: visual field.
Box 1. Description of the pathways compared within the economic model.
Glaucoma Screening Platform Study (GPS)1. (Tonometry (measurement of intraocular pressure (IOP)) and optic nerve photography
(ONP)): The population to be screened are invited to a primary care setting to undergo tonometry and ONP by a technician or nurse
who has received some training. Screen positives referred to hospital eye service.
GPS11 (IOP and visual field (VF)): As above but screening with tonometry and visual field test (perimetry). Screen positives referred to
hospital eye service.
GPS1d (IOPþONP): Screening with tonometry and optic nerve photography and screen positives examined by a specialized optom-
etrist (diagnosis). Diagnostic test positives referred to hospital eye service.
GPS11d (IOPþ VF): Screening with tonometry and visual field test (perimetry) with further diagnostic refinement and screen positives
examined by a specialized optometrist (diagnosis). Diagnostic test positives referred to hospital eye service.
Current practice (UK NHS eye care): Opportunistic sight test at community optometrist with referral of suspect glaucoma to the hospital
eye service.
IOP 26mmHg¼ screen positive.
IOP< 26mmHgþ second technology test positive¼ screen positive.
IOP< 26mmHgþ second technology test negative¼ return to current eye care and re-screen cycle.
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For a higher risk subgroup (assumed glaucoma
prevalence of 5%) a targeted screening programme
(surveillance) could be worthwhile if the annual cost
of sight impairment is above £3000 (Figure 1(b)).
Assuming a low uptake of current eye care (6.5%
per year), as might be expected within a low income
subgroup screening could be considered cost-eﬀective
if the annual cost of visual impairment is above
£18,000 per year with screening uptake of 40% for a
cohort with an assumed glaucoma prevalence of 1%
(Figure 1(c)).
Enhancing current eye care. Increasing the uptake of cur-
rent eye care for those in higher risk groups (>5% glau-
coma prevalence), as opposed to a screening
programme, is cost-eﬀective when the annual cost of
sight impairment is above £8000 and assuming no
cost for a behavioural intervention to improve
Table 1. Prevalence, incidence and progression of glaucoma.
Probability Value Source
Prevalence of glaucoma 1–5% Assumption based on prevalence rates for
general population and high prevalence
subgroups5,14
Progression to moderate glaucomaa 0.129 Progression data from GSM 20075,14
Progression to severe glaucoma 0.048 Progression data from GSM 20075,14
Progression to visual impaired 0.042 Progression data from GSM 20075,14
Annual probability of having an eye test in
current practice (not screening):
General population (adults over 40 years old) 0.1728 Based on survey of the UK public21
General population (adults over 40 years old) 0.0741 Based on BHPS data and alternative
assumptions22
Individuals with diabetes 0.1693 Based on BHPS data22
Individuals with eye problems 0.1192 Based on BHPS data22
Individuals within low income households 0.0653 Based on BHPS data22
Visual field based glaucoma staging5 Mean defect score (dB)
Mild glaucoma 001 to 600 dB
Moderate glaucoma 601 to 1200 dB
Severe glaucoma 1201 to 2000 dB
Visual impairment (partial sight/blind) 2001 dB or worse
GSM: Glaucoma Screening Model; BHPS: British Household Panel Survey.
aVisual field based glaucoma staging.
Table 2. Data on screening tests and test performance.
Probability Value Source
Current eye care
Optometry testing, sensitivity 0.32 GSM 20075
Optometry testing, specificity 0.99 GSM 20075
Proportion of normal (no glaucoma) with IOP< 26mmHg 0.96 GSM 20075
Proportion of glaucoma with IOP 26mmHg 0.35 GSM 20075
Screening tests
Optic nerve photography, sensitivity 0.73 GSM 20075
Optic nerve photography, specificity 0.89 GSM 20075
Perimetry (Frequency Doubling Technology-C-20-1), sensitivity 0.79 GSM 20075
Perimetry (Frequency Doubling Technology-C-20-1) specificity 0.94 GSM 20075
IOP: intraocular pressure; GSM: Glaucoma Screening Model.
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uptake. Increasing uptake rates would, however, be
likely to incur costs. The cost per individual of increas-
ing uptake would need to be <£20 with an annual cost
of sight impairment per person of £20,000 for this strat-
egy to approach cost-eﬀectiveness.
The cost of sight impairment is uncertain. This
uncertainty was built into the probabilistic sensitivity
analysis by investigating the impact of the annual cost
of visual impairment being equally likely to have any
value between £1000 and £40,000 (i.e. assuming a uni-
form distribution) and investigating the value of remov-
ing all the imprecision around parameter estimates
within the model, i.e. the EVPI as well as the value of
removing all uncertainty surrounding a particular
(group of) parameter(s), i.e. EVPPI. Figure 2 shows
the average EVPI and EVPPI curves for a 50-year-old
cohort with a 5% prevalence rate of glaucoma (higher
risk subgroup) and when uptake of current practice is
7.4% (described in Table 1). This situation was chosen
as, based on the base case results, was the most likely
scenario favouring screening. The value of removing
the imprecision around the model parameter estimates
is illustrated in Figure 2.
The peak in the EVPI curve corresponds to the
willingness to pay for a QALY value where decision
uncertainty is at its highest (at around £20,000 WTP)
and is the decision point on whether to screen or not.
For a willingness to pay threshold of £20,000 for a
QALY, the population EVPI is around £107 million,
with the costs of sight impairment contributing
the most to this decision uncertainty (EVPPI, £74
million), followed by the uncertainty due to test per-
formance (e.g. £14 million), and screening acceptance
or current practice eye uptake rate (e.g. £8 million
each).
Discussion
Main findings
Findings from the original Glaucoma Screening Model
had suggested that glaucoma screening of a population
selected on age is unlikely to be considered cost-
eﬀective at values for a QALY that society is typically
willing to pay, but screening of high risk groups (preva-
lence of around 4%) might be. Across all the scenarios,
we modelled the conclusion from the original evalu-
ation is unchanged. Results were robust to all changes
in the model parameter values except for the annual
cost of sight impairment. When taking a wider perspec-
tive on the costs of sight impairment, ﬁndings from the
two way sensitivity analysis, varying screening uptake
and costs of sight impairment, suggest that assuming
higher estimated costs of sight impairment screening
the general population selected on age alone as opposed
to surveillance of high risk groups might be worthwhile.
Data on the annual cost of sight impairment are very
limited. The health costs of severe sight impairment due
to glaucoma have been estimated as £800 per year
(updated to 2010–2011 prices).27 For adults with
Table 3. Cost-effectiveness base case analysisa results.
Screening acceptance (%) Strategy Cost QALYs ICERb
Current practice £176 19.2530
30% GPS IId (IOPþVF) £239 19.2537 88,908
GPS Id (IOPþONP) £239 19.2536 (Dominated)
GPS II (IOPþVF) £266 19.2540 97,136
GPS I (IOPþONP) £276 19.2539 (Dominated)
Current practice £176 19.2530
50% GPS IId (IOPþVF) £261 19.2539 74,408
GPS 1d (IOPþONP) £261 19.2538 (Dominated)
GPS II (IOPþVF) £304 19.2543 103,985
GPS I (IOPþONP) £321 19.2541 (Dominated)
Current practice £176 19.2530
70% GPS IId (IOPþVF) £282 19.2541 68,718
GPS 1d (IOPþONP) £283 19.2540 (Dominated)
GPS II (IOPþVF) £342 19.2545 111,427
GPS I (IOPþONP) £366 19.2544 (Dominated)
QALY: quality adjusted life years; ICER: incremental cost-effectiveness ratio; IOP: intraocular pressure; GPS: Glaucoma screening
Platform Study; VF: visual field.
aForty-year-old inception cohort, 17% uptake of current practice, 1% glaucoma prevalence, lifetime time horizon, NHS costs.
bICERs are related to the, on average, cheapest non-dominated strategy.
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physical disabilities, additional social care costs are esti-
mated at £41,000 per year. These data include estimates
from people with sight loss but data were not reported
separately.24 The cost of sight impairment in the UK is
reported by the Royal National Institute for the Blind
as £12,457 per person per year.28 However, these calcu-
lations include indirect costs (productivity losses), cost
due to lower employment, premature mortality, as well
as £8782 corresponding to burden of disease cost – the
use of such ﬁgures entails some double counting as
some of these eﬀects are captured within the QALY
estimates. Estimates by Mead and Hyde suggest that
the cost of blindness for another chronic eye condition,
age related macular degeneration, range around £8000
(updated to 2010–2011 prices) for the ﬁrst year of blind-
ness but highlighted the limitations in the data to deter-
mine the true costs of failing eyesight.29
The purpose of updating the original Glaucoma
Screening Model was to determine whether, given the
newly deﬁned screening pathways and target popula-
tion, a large glaucoma screening RCT would be value
for money in terms of informing policy decisions. The
value of removing all uncertainties in the model was
around £107 million, indicating that further research
on glaucoma screening might be worthwhile. The
uncertainty around cost of sight impairment
contributed most followed by the uncertainty around
screening test performance, and the uptake of screening
or current eye care services.
These ﬁndings suggest that before proceeding to a
large RCT evaluating a glaucoma screening or surveil-
lance programme, further research to understand and
quantify the cost of sight impairment is a priority.
These data would be best collected within a prospective
cohort study, following individuals through the spec-
trum of visual impairment and as needs change and
adaptation to sight loss occurs.
The eﬀectiveness of any screening or surveillance
programme requires that the target population attend.
Our ﬁndings suggest that behavioural intervention,
such as a carefully worded invitation with a reminder
or a more intensive intervention (e.g. tailored message,
SMS reminder, buddy system) may improve
attendance.21
Strengths and limitations
This study used a transparent iterative approach build-
ing on a robust evidence synthesis and sought views of
all stakeholders to inform decisions regarding glau-
coma screening. We used robust qualitative and quan-
titative methods to provide an evidence-based
Figure 2. Average expected value of perfect information (EVPI) and expected value of parameter perfect information (EVPPI).
Scenario: model start age (and screening) 50 years old, prevalence rate 5%, screening every 10 years, whole population, current
practice annual eye test uptake rate 7.4%, average annual cost of sight impairment £20,500. The upper and lower bounds limits for this
distribution were informed by the literature,27,28 assuming that NHS treatment as well as PSS cost were included. Incremental cost-
effectiveness ratio for moving to screening (GPS1d (IOPþVF)¼ £21,720). The peak in EVPI corresponds to the uncertainty in the
decision of changing from current practice (opportunistic case finding) to screening with a technician conducting tonometry and visual
field test (perimetry) with screen positives examined by a specialized optometrist (GPS11d (IOPþVF)). EVPPI shown for selected
parameters that contributed the most to decision uncertainty. IOP: intraocular pressure; GPS: Glaucoma screening Platform Study;
PSS: personal social services; VF: visual field.
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recommendation for future research. It was not within
the scope of this study to estimate the accuracy of
screening tests or to evaluate the accuracy of current
eye care services in the detection of glaucoma. We used
the same estimates of performance of community opto-
metric detection of glaucoma (current eye care) as used
in the original model, based on a survey in the late
1980s which may not represent current practice. To
estimate screening test performance we used estimates
from an evidence synthesis but these were based on
evidence from studies with heterogeneous populations
and high risk of bias.
We had limited data on the uptake of current eye
care services by higher risk groups, particularly by
ethnic minority groups and those who might expect to
have a higher uptake of current eye care, those with a
family history of glaucoma. We did however use new
primary data from our survey on eye testing within the
last few years and used data from the BHPS that is
considered to be representative.
The value for information analysis can only capture
those uncertainties incorporated into the economic
model and is dependent on the model structure. The
model did not consider the potential harms due to
screening (e.g. anxiety for those with false positives)
or the side eﬀects of treatment (e.g. cataracts). While
it is unlikely that these omissions would have a major
impact on the model results, they are a limitation of the
analysis. Finally, while the EVPI analysis constitutes a
necessary condition in determining whether further
research is worthwhile it is not in itself suﬃcient to
determine whether research should be conducted
(although it can give a strong indication that further
research is not worthwhile, if for example EVPI is less
than the costs of conducting further research). A posi-
tive expected net-beneﬁt of sampling (ENBS) consti-
tutes a necessary and suﬃcient condition to conduct
further research. ENBS is the diﬀerence between the
beneﬁts of reducing uncertainty with a particular
sample size study and the cost of obtaining that
sample size. Unfortunately, ENBS can be obtained
only under very restrictive assumptions and is often
computationally prohibitive and there have been few
examples where it has been used in practice to
inform, for example, the sample size of a trial.30 In
such circumstances, we believe the EVPI establishes a
ﬁrst step to inform the judgment that further research is
potentially worthwhile.
Conclusions
A glaucoma screening trial is currently unlikely to be
the best use of research resources to inform policy deci-
sions on screening policy in the UK. Further research
to quantify the health and personal social services costs
of sight impairment is recommended. Further develop-
ment of glaucoma tests and an evaluation of a behav-
ioural intervention to improve attendance for those
who do not use eye care services would be worthwhile.
Our ﬁndings are UK speciﬁc, but the methods used and
the modelling framework can be adapted and popu-
lated with country speciﬁc parameters.
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